Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odronextamab + CHOP
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Odronextamab + CHOP is a combination therapy under clinical investigation for untreated or relapsed/refractory B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Odronextamab is a CD20×CD3 bispecific monoclonal antibody that redirects T cells to trigger cytotoxicity of malignant B cells by binding CD20 on B cells and CD3 on T cells. CHOP is a standard chemotherapy regimen that includes cyclophosphamide (alkylating agent), doxorubicin (DNA intercalating agent), vincristine (mitotic inhibitor), and prednisone (corticosteroid). The combination aims to synergistically enhance antitumor responses: CHOP provides cytotoxic chemotherapy, while odronextamab engages T cells for targeted cell killing through immunotherapy mechanisms. Clinical trials are evaluating safety and efficacy, especially in high-risk, previously untreated patients and those with relapsed/refractory disease[1][5][3].
- Other names
- odronextamab plus CHOPodronextamab combined with CHOPO-CHOPOdro-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on odronextamab + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odronextamab + CHOP.